12th HTAsiaLink Conference 2025
Start on 19 Aug 2025
End on 22 Aug 2025
Location:
Singapore EXPO
1 Expo Drive, Singapore 486150
Theme:
Unlocking Value through Health Technology Assessment (HTA) in Asia: Forging Ahead Together
Join us in Singapore for the 12th HTAsiaLink Conference in 2025, where experts and leaders from the Asia Pacific region will converge to explore and advance the role of Health Technology Assessment (HTA) in unlocking value within our healthcare systems. The 2025 conference theme emphasises the power of collaboration as we forge ahead together, addressing shared challenges and opportunities in the region.
Who Should Attend:
- Members and associate members of HTAsiaLink
There are no fees for participating in the conference and all members are responsible for their own costs.
Stay tuned for detailed conference information, including the conference programme and keynote speakers. Registration will open soon!
Schedule-at-a-Glance
Plenary 1
Exploring the Multiverse of Healthcare through HTA: Diverse perspectives, unified outcomes
This plenary focuses on the diversity of HTA in terms of methodologies, types of health technologies or programs, and initiatives shaping the dynamic landscape. The diverse ways HTA is used across countries and settings, HTA harmonisation efforts, methods for equitable evaluation in HTA, and the importance of the patient perspective in HTA are the main themes that will be discussed.
Moderator | Panelists |
---|
A/Prof Wanrudee Isaranuwatchai Health Intervention and Technology Assessment Program (HITAP) Thailand | Dr Eri Hoshino Center for Outcomes Research and Economic Evaluation for Health (C2H), Japan. As a member of INAHTA Topic: Diversity of HTA approaches across countries/settings & associated challenges; insights beyond Asia Pacific Ms Anne Julienne Marfori Department of Science and Technology (DOST) Philippines Topic: ASEAN HTA Harmonization Project: Common assessment methods, reporting formats & joint assessments in HTAs in the region Prof Sitanshu Sekhar Kar Equity in Asia-Pacific Health Systems (EquitAP-HTA) Topic: Addressing equity in HTA: Insights and Applications of Distributional Cost-Effectiveness Analysis (DCEA) in policy making Dr Simon Fifer Community and Patient Preference Research (CaPPRe) Topic: Importance of incorporating patient preference data into HTA as real-world evidence |
Plenary 2
The Road Ahead: Navigating Possibilities with HTA
This plenary session, co-organised with Saw Swee Hock School of Public Health, will explore the critical role of HTA in shaping the future of data-driven, artificial intelligence (AI)-empowered personalised medicine (PM). The advent of big health data analytics has enabled the synergies between AI and PM, which are mainly divided into four groups: digital diagnostics, therapy planning, risk prediction, disease self-management. As these innovative technologies rapidly and simultaneously evolve, HTA serves as a key framework to assess their clinical effectiveness, economic value, equity and ethical implications, ensuring they deliver meaningful benefits to patients and healthcare systems.
Moderator | Panelists |
---|
A/Prof Wee Hwee Lin Saw Swee Hock School of Public Health Singapore | Kelly Lenahan The professional society for health economics and outcomes research ISPOR Topic: Updates from ISPOR Global HTA Roundtable with focus on successes & opportunities; Results from use of AI in HEOR ISPOR workgroup A/Prof Chen Wenjia Saw Swee Hock School of Public Health Singapore Topic: Overview of the current landscape of HTA and reimbursement of AI-PM Dr Mark Sculpher University of York United Kingdom Topic: Methodologies of evaluation of AI-PM in HTA Dr Xiao Yue National Center for Medicine and Health Technology Assessment of China Topic: Real-world practice and challenges in evaluating AI-PM with HTA; the China experience |
Plenary 3
Translating HTA into Impactful Results: Value-based Healthcare
The session discusses how HTA helps to achieve value-based healthcare (VBHC), showcasing the importance of implementation strategies to drive adoption of cost-effective health technologies, and measurement systems to understand the impact of HTA on health outcomes and healthcare systems. International health economics outcomes research, translation of evidence to policy guidelines at a national level, the role of price volume agreements and risk sharing agreements in VBHC, and perspectives on the practical application of VBHC towards tangible measurable outcomes will be discussed.
Moderator | Panelists |
---|
Dr Huang Li-Ying (Grace) Center for Drug Evaluation Taiwan | Dr Joanne Yoong The professional society for health economics and outcomes research ISPOR VBHC taskforce Topic: Findings & recommendations on role of HEOR and HTA in VBHC implementation from ISPOR VBHC Task Force Dr Kavitha Rajsekar Ministry of Health and Family Welfare India Topic: Translation of HTA evidence into policy guidelines for cost saving at a national level in India Ms Lin Liang Agency for Care Effectiveness Singapore Topic: Role and use of HTA in implementing VBHC in Singapore Dr Yot Teerawattananon Health Intervention and Technology Assessment Program (HITAP) Thailand Topic: Translation of HTA into meaningful preventive services & public health programmes Dr Wija Oortwijn Radboud University Medical Center, the Netherlands |
Sharing Session by Prof Mark Jit and Prof Alex Cook
Prof Mark Jit and Prof Alex Cook will present the draft recommendations of the Lancet Commission on epidemiological modelling, and the evidence that informed them. They will then discuss how the recommendations can be used to support health technology assessment of infectious disease interventions.
Speakers |
---|
Prof Mark Jit London School of Hygiene & Tropical Medicine United Kingdom Prof Alex Cook Saw Swee Hock School of Public Health Singapore |
PRE-CONFERENCE WORKSHOP SCHEDULE
Legend
Blue: Exploring the Multiverse of Healthcare through HTA
Purple: The Road Ahead: Navigating AI-empowered Precision Medicine Possibilities with HTA
Orange: Translating HTA into Impactful Results: Value-Based Healthcare
CALL FOR ABSTRACTS
We are now accepting abstracts for the 2025 Conference! The Conference offers an exceptional platform to showcase your research and engage with peers.
There are 3 tracks available for abstract submission:
Track 1: Economic Evaluation | Track 2: Health Services Research | Track 3: Others |
---|
Economic evaluation topic areas include: · Cost studies (including cost of illness and resource use) · Cost comparison · Budget impact analysis · Thresholds and opportunity cost · Trial-based economic evaluation · Indirect health costs · Value of information · Novel and social elements of value.1 | Health services research is the multidisciplinary field of scientific investigation that studies how · Social factors · Financing systems · Organizational structures and processes · Health technologies · Personal behaviours affect access to health care, the quality and cost of health care, and ultimately our health and well-being.2 Topic areas include policy analysis, qualitative studies or mixed methods. | This track encompasses all research areas not specifically covered in Track 1 or 2. It can include diverse health-related studies, including but not limited to: · Evidence synthesis: systematic reviews, meta-analysis, network meta-analysis, scoping reviews · Data science: observational studies, real-world evidence |
Abstract Submission Guideline:
Please refer to the submission guidelines document below on how to submit an abstract.
Download here
Abstract Template Form:
Please use the abstract template form below to submit your abstract.
Download here
Abstract Submission Format:
All abstracts must be submitted electronically VIA THIS LINK.
Enquiries:
For enquires on the abstract submissions, please contact the HTAsiaLink Conference 2025 Committee at htasialink_2025_secretariat@moh.gov.sg.